Patents by Inventor Michael Nebozhyn
Michael Nebozhyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220380854Abstract: The invention relates to (i) an angiogenesis gene signature and (ii) a monocytic myeloid-derived suppressor cell (mMDSC) gene signature that are each predictive of patient response to treatment with a PD-1 antagonist, wherein the angiogenesis signature comprises five or more genes. More specifically, a lower angiogenesis score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Similarly, a lower mMDSC score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as either (i) positive for the angiogenesis gene signature biomarker of the invention or (ii) positive for the mMDSC gene signature biomarker of the invention.Type: ApplicationFiled: October 29, 2020Publication date: December 1, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Mark D. Ayers, Razvan Cristescu, Andrey Loboda, Jared K. Lunceford, Hua Ma, Terrill K. McClanahan, Michael Nebozhyn, Chunsheng Zhang
-
Patent number: 11377693Abstract: A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.Type: GrantFiled: December 8, 2015Date of Patent: July 5, 2022Assignee: Merck Sharp & Dohme LLCInventors: Mark D. Ayers, Andrey Loboda, Jared K. Lunceford, Terrill K. McClanahan, Erin E. Murphy, Michael Nebozhyn
-
Patent number: 11326211Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.Type: GrantFiled: April 12, 2016Date of Patent: May 10, 2022Assignee: Merck Sharp & Dohme Corp.Inventors: Mark Ayers, Jared Lunceford, Andrey Loboda, Michael Nebozhyn, Terrill K. McClanahan, Heather Hirsch
-
Publication number: 20220112564Abstract: The invention relates to a stromal/EMT/TGF? signature that is predictive of patient response to treatment with a PD-1 antagonist, wherein the stromal/EMT/TGF? signature comprises five or more genes selected from Table 1 disclosed herein. More specifically, a lower stromal/EMT/TGF-? score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as positive for the stromal/EMT/TGF? biomarker of the invention. The disclosure also provides methods and kits for testing tumor samples for the biomarkers.Type: ApplicationFiled: February 10, 2020Publication date: April 14, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Andrey Loboda, Jared K. Lunceford, Chunsheng Zhang, Michael Nebozhyn, Razvan Cristescu, Mark D. Ayers, Terrill K. McClanahan, Hua Ma
-
Publication number: 20180327848Abstract: A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.Type: ApplicationFiled: December 8, 2015Publication date: November 15, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Mark D. Ayers, Andrey Loboda, Jared K. Lunceford, Terrill K. McClanahan, Erin E. Murphy, Michael Nebozhyn
-
Publication number: 20180148790Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.Type: ApplicationFiled: April 12, 2016Publication date: May 31, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Mark Ayers, Jared Lunceford, Andrey Loboda, Michael Nebozhyn, Terrill K. McClanahan, Heather Hirsch
-
Publication number: 20160312295Abstract: The present disclosure describes gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.Type: ApplicationFiled: December 15, 2014Publication date: October 27, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Mark Ayers, Andrey Loboda, Jared Lunceford, Terrill K. McClanahan, Erin Murphy, Michael Nebozhyn, Robert H. Pierce
-
Publication number: 20160312297Abstract: The present disclosure describes PD-L1 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.Type: ApplicationFiled: December 15, 2014Publication date: October 27, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Mark Ayers, Andrey Loboda, Jared Lunceford, Terrill K. McClanahan, Erin Murphy, Michael Nebozhyn, Robert H. Pierce
-
Publication number: 20160304969Abstract: The present disclosure describes IFN-? gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.Type: ApplicationFiled: December 15, 2014Publication date: October 20, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Mark Ayers, Andrey Loboda, Jared Lunceford, Terrill K. McClanahan, Erin Murphy, Michael Nebozhyn, Robert H. Pierce
-
Publication number: 20140304845Abstract: Methods, biomarkers, and expression signatures are disclosed for assessing the disease progression of Alzheimer's disease (AD). In one embodiment, BioAge (biological age), NdStress (neurodegenerative stress), Alz (Alzheimer), and Inflame (inflammation) are used as biomarkers of AD progression. In another aspect, the invention comprises a gene signature for evaluating disease progression. In still another embodiment, methods for evaluating disease progression are provided. In yet another embodiment, the invention can be used to identify animal models for use in the development and evaluation of therapeutics for the treatment of AD.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Andrey Loboda, Michael Nebozhyn, Alexei Podtelezhnikov, David J. Stone, Keith Tanis, William J. Ray
-
Publication number: 20140031251Abstract: In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting cancer patient prognosis based on whether the cancer is classified as having a high or low EMT Signature Score.Type: ApplicationFiled: November 2, 2011Publication date: January 30, 2014Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Merck Sharp & Dohme Corp.Inventors: Timothy Yeatman, Andrey Loboda, Michael Nebozhyn, Hongyue Dai
-
Publication number: 20140030255Abstract: In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting whether a subject with cancer will respond to treatment with an agent, based on whether the cancer is classified as having a high or low EMT Signature Score.Type: ApplicationFiled: November 2, 2011Publication date: January 30, 2014Applicant: MERCK SHARP & DOHME CORP.Inventors: Andrey Loboda, Michael Nebozhyn, Hongyue Dai
-
Patent number: 8392127Abstract: Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of growth factor pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating growth factor pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated growth factor signaling pathway; determining whether an agent modulates the growth factor signaling pathway in sample; predicting response of a subject to an agent that modulates the growth factor signaling pathway; assigning treatment to a subject; and predicting evaluating the pharmacodynamic effects of cancer therapies designed to regulate growth factor pathway signaling.Type: GrantFiled: March 19, 2009Date of Patent: March 5, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: James Watters, Andrey Loboda, Michael Nebozhyn
-
Publication number: 20110015869Abstract: Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of growth factor pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating growth factor pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated growth factor signaling pathway; determining whether an agent modulates the growth factor signaling pathway in sample; predicting response of a subject to an agent that modulates the growth factor signaling pathway; assigning treatment to a subject; and predicting evaluating the pharmacodynamic effects of cancer therapies designed to regulate growth factor pathway signaling.Type: ApplicationFiled: March 19, 2009Publication date: January 20, 2011Inventors: James Watters, Andrey Loboda, Michael Nebozhyn
-
Publication number: 20100280987Abstract: Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of RAS pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating RAS pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated RAS signaling pathway; determining whether an agent modulates the RAS signaling pathway in sample; predicting response of a subject to an agent that modulates the RAS signaling pathway; assigning treatment to a subject; and evaluating the pharmacodynamic effects of cancer therapies designed to regulate RAS pathway signaling.Type: ApplicationFiled: April 16, 2010Publication date: November 4, 2010Inventors: Andrey Loboda, Michael Nebozhyn, Theresa Zhang, James W. Watters, Pearl S. Huang, Michael Chastain, Richard A. Klinghoffer
-
Patent number: 7640114Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.Type: GrantFiled: May 21, 2004Date of Patent: December 29, 2009Assignee: The Wistar Institute of Anatomy & BiologyInventors: Louise C. Showe, Michael K. Showe, Laszlo Kari, Michael Nebozhyn, Andrey Loboda
-
Patent number: 7514219Abstract: The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.Type: GrantFiled: November 16, 2006Date of Patent: April 7, 2009Assignees: The Wistar Institute, Trustees of the University of PennsylvaniaInventors: Louise C. Showe, Michael Nebozhyn, Anil Vachani, Steven M. Albelda
-
Publication number: 20070264644Abstract: The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.Type: ApplicationFiled: November 16, 2006Publication date: November 15, 2007Inventors: Louise Showe, Michael Nebozhyn, Anil Vachani, Steven Albelda
-
Publication number: 20060271309Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.Type: ApplicationFiled: May 21, 2004Publication date: November 30, 2006Applicant: The Wistar Institute of Anatomy and BiologyInventors: Louise Showe, Michael Showe, Laszlo Kari, Michael Nebozhyn, Andrey Loboda